| Patents for A61P 35 - Antineoplastic agents (221,099) |
|---|
| 04/09/2009 | US20090092545 Antibodies that bind both bcma and taci |
| 04/09/2009 | DE4021517B4 Formulierungen mit verlangsamter Freisetzung wasserlöslicher Peptide Formulations with delayed release of water-soluble peptides |
| 04/09/2009 | DE102007047738A1 Imidazolderivate Imidazole derivatives |
| 04/09/2009 | DE102007047735A1 Thiazolderivate Thiazole derivatives |
| 04/09/2009 | DE102007046202A1 Medium for preventing or relieving pain, muscular strain particularly in muscle, for improvement of immune condition, wound healing or for reduction or recovery of arteriosclerosis, has mixture of tocotrienols and gamma linolenic acid |
| 04/09/2009 | CA2738980A1 Pyrazin-2-yl-pyridin-2-yl-amine and pyrazin-2-yl-pyrimidin-4-yl-amine compounds and their use |
| 04/09/2009 | CA2710406A1 Use of a peptide as a therapeutic agent |
| 04/09/2009 | CA2701778A1 Crystalline peptide epoxy ketone protease inhibitors and the synthesis of amino acid keto-epoxides |
| 04/09/2009 | CA2701768A1 Thiophene-2-carboxamide derivatives as modulators of ccr9 receptor |
| 04/09/2009 | CA2701686A1 Methods of treating cancer using notch pathway inhibitors |
| 04/09/2009 | CA2701630A1 Quinolone analogs and methods related thereto |
| 04/09/2009 | CA2701581A1 Pyrimidine substituted purine derivatives |
| 04/09/2009 | CA2701537A1 Compositions for treatment of tumors by direct administration of a radioisotope |
| 04/09/2009 | CA2701406A1 Benzoxazinone derivative |
| 04/09/2009 | CA2701368A1 A composition containing non-psychotropic cannabinoids for the treatment of inflammatory diseases. |
| 04/09/2009 | CA2701274A1 Lipopeptides for delivery of nucleic acids |
| 04/09/2009 | CA2701124A1 C-met protein kinase inhibitors |
| 04/09/2009 | CA2701115A1 N-hydroxy-naphthalene dicarboxamide and n-hydroxy-biphenyl-dicarboxamide compounds as histone deacetylase inhibitors |
| 04/09/2009 | CA2700903A1 Parp inhibitor compounds, compositions and methods of use |
| 04/09/2009 | CA2700860A1 Human antibodies that bind mesothelin, and uses thereof |
| 04/09/2009 | CA2700857A1 Hdac inhibitors |
| 04/09/2009 | CA2700617A1 Tumor suppression using human placental perfusate and human placenta-derived intermediate natural killer cells |
| 04/09/2009 | CA2700410A1 Treatment of proliferative disorders using antibodies to psma |
| 04/09/2009 | CA2699601A1 Nlrr-1 antagonists and uses thereof |
| 04/09/2009 | CA2699264A1 Substance p and thyrotropin releasing hormone for therapeutic applications |
| 04/09/2009 | CA2699260A1 Use of a peptide as a therapeutic agent |
| 04/09/2009 | CA2699255A1 Use of a peptide as a therapeutic agent |
| 04/09/2009 | CA2699114A1 Use of a peptide as a therapeutic agent |
| 04/09/2009 | CA2699113A1 Use of a peptide as a therapeutic agent |
| 04/09/2009 | CA2699109A1 Use of urocortin and corticotropin-releasing factor as therapeutic agents |
| 04/09/2009 | CA2699107A1 Use of a platelet fibrinogen receptor hexapeptide antagonist and alpha-endorphin as therapeutic agents |
| 04/09/2009 | CA2699105A1 Use of a peptide as a therapeutic agent |
| 04/09/2009 | CA2699104A1 Use of a peptide as a therapeutic agent |
| 04/09/2009 | CA2699078A1 Use of grf-1 (1-29 ) and corticotropin-releasing factor as therapeutic agents |
| 04/09/2009 | CA2699074A1 Use of a peptide as a therapeutic agent |
| 04/09/2009 | CA2699067A1 Use of rfrp, alone or in combination with neurokinin-b, as a therapeutic agent |
| 04/09/2009 | CA2698928A1 Compounds and methods for treating zinc matrix metalloprotease dependent diseases |
| 04/09/2009 | CA2698690A1 Thyrotropin releasing hormone for therapeutic applications |
| 04/09/2009 | CA2698688A1 Use of a peptide as a therapeutic agent |
| 04/09/2009 | CA2698687A1 Use of a peptide as a therapeutic agent |
| 04/09/2009 | CA2694322A1 1-oxo-isoindoline-4-carboxamide and 1-oxo-1,2,3,4-tetrahydroisoquinoline-5-carboxamide derivatives, preparation and therapeutic use thereof |
| 04/09/2009 | CA2694313A1 Derivatives of 1-oxo-1,2-dihydroisoquinoline-5-carboxamides and of 4-oxo-3,4-dihydroquinazoline-8-carboxamides, preparation thereof and application thereof in therapeutics |
| 04/08/2009 | EP2045270A2 Taxanes covalently bounded to hyaluronic acid or hyaluronic acid derivatives |
| 04/08/2009 | EP2045258A1 3'-ethynylcytidine derivative |
| 04/08/2009 | EP2045256A1 2'-cyanopyrimidine nucleoside compound |
| 04/08/2009 | EP2045253A1 a-AMINO ACID DERIVATIVE AND PHARMACEUTICAL COMPRISING THE SAME AS ACTIVE INGREDIENT |
| 04/08/2009 | EP2045251A1 Compound that can inhibit ubc13-uev interactions, pharmaceutical compositions and therapeutic uses |
| 04/08/2009 | EP2045247A1 Compounds for the inhibition of histone deacetylase |
| 04/08/2009 | EP2045245A1 Inreversible protein tyrosine kinases inhibitors and the preparation methods and uses thereof |
| 04/08/2009 | EP2045239A1 Novel derivatives of phthalimide as histone deacetylase inhibitors |
| 04/08/2009 | EP2044961A2 Phospholipid analogues for the treatment of cancers |
| 04/08/2009 | EP2044956A1 Hematopoietic stem cell proliferation promoter |
| 04/08/2009 | EP2044955A2 Methods for detecting and inhibiting angiogenesis |
| 04/08/2009 | EP2044953A1 Viral antigens |
| 04/08/2009 | EP2044952A2 Use of the pedf factor to induce cell regeneration |
| 04/08/2009 | EP2044949A1 Use of recombinant lag-3 or the derivatives thereof for eliciting monocyte immune response |
| 04/08/2009 | EP2044948A1 Methods and compositions concerning poxviruses and cancer |
| 04/08/2009 | EP2044935A1 A composition containing non-psychotropic cannabinoids for the treatment of inflammatory diseases |
| 04/08/2009 | EP2044125A1 Compositions and methods for delivering anti-activated ras antibodies into cells |
| 04/08/2009 | EP2044122A2 Antagonist antibody against epha2 for the treatment of cancer |
| 04/08/2009 | EP2044119A1 Cancerous disease modifying antibodies |
| 04/08/2009 | EP2044084A2 Mtki quinazoline derivatives |
| 04/08/2009 | EP2044080A1 Camptothecin derivatives with antitumor activity |
| 04/08/2009 | EP2044079A1 Camptothecin derivatives with antitumor activity |
| 04/08/2009 | EP2044078A1 Camptothecin derivatives with antitumor activity |
| 04/08/2009 | EP2044075A1 Furo [3, 2-b] pyrrol derivatives |
| 04/08/2009 | EP2044071A1 OOXO-SUBSTITUTED IMIDAZO[1,2b]PYRIDAZINES, PRODUCTION AND USE THEREOF AS DRUGS |
| 04/08/2009 | EP2044065A2 Compounds and compositions as hedgehog pathway modulators |
| 04/08/2009 | EP2044063A1 Pyrimidine derivatives useful in the treatment of cancer |
| 04/08/2009 | EP2044058A1 Chemical compounds |
| 04/08/2009 | EP2044053A2 Urea compounds useful in the treatment of cancer |
| 04/08/2009 | EP2044036A1 [4,5']bipyrimidinyl-6,4'-diamine derivatives as protein kinase inhbitors |
| 04/08/2009 | EP2044026A1 Method of treatment of glioma brain tumour |
| 04/08/2009 | EP2043689A2 Drug delivery with stimulus responsive biopolymers |
| 04/08/2009 | EP2043665A2 Composition for the enterosorption and management of toxins comprising a calcium aluminosilcilate clay |
| 04/08/2009 | EP2043659A1 Anti-cancer therapy comprising an h2-blocker, at least one antiinflammatory agent and a cytotoxic agent |
| 04/08/2009 | EP2043656A2 New medical use of triazine derivatives |
| 04/08/2009 | EP2043655A2 Purine and deazapurine derivatives as pharmaceutical compounds |
| 04/08/2009 | EP2043653A2 Crystalline forms of gemcitabine amide prodrug, compositions and use thereof |
| 04/08/2009 | EP2043652A2 Use of fosfluridine tidoxil (ft) for the treatment of intraepithelial proliferative diseases |
| 04/08/2009 | EP2043651A2 Methods of using igf1r and abl kinase modulators |
| 04/08/2009 | EP2043645A2 Compounds and compositions for treatment of cancer |
| 04/08/2009 | EP2043633A2 Thiadiazolidinone derivatives |
| 04/08/2009 | EP2043632A2 New indications for direct thrombin inhibitors |
| 04/08/2009 | EP1931671B1 Alkyl 4- [4- (5-oxo-2, 3, 5, 11a-tetrahyd0-5h-pyrr0l0 [2, 1-c][1, 4]benzodiazepine-8-yloxy) -butyrylamino]-1h-pyrrole-2-carboxylate derivatives and related compounds for the treatment of a proliferative disease |
| 04/08/2009 | EP1831198B1 Pyridine carboxamide derivatives for use as anticancer agents |
| 04/08/2009 | EP1673065B1 Microemulsions of retinoids, and pharmaceutical compositions containing them |
| 04/08/2009 | EP1565475B1 Diazinopyrimidines and their use as protein kinase inhibitors |
| 04/08/2009 | EP1545710B1 Use of n-(3-methoxy-5-methylpyrazin-2-yl)-2-(4-[1,3,4-oxadiazol-2-yl]phenyl)pyridine-3-sulphonamide in the treatment of cancer |
| 04/08/2009 | EP1519749B1 Chemotactic factor inhibitor for inhibiting inflammatory reactions |
| 04/08/2009 | EP1501921B1 Improved viral purification methods |
| 04/08/2009 | EP1461340B1 Trioxane derivatives as antimalaria or anticancer compounds |
| 04/08/2009 | EP1442026B1 Triazole derivatives as cyclooxygenase (cox) inhibitors |
| 04/08/2009 | EP1430023B1 Substituied urea retinoid agonists ii |
| 04/08/2009 | EP1409076A4 Method and apparatus for treating tumors using low strength electric fields |
| 04/08/2009 | EP1250353B1 P21 derived peptides capable of inhibiting cdk/cyclin complexes |
| 04/08/2009 | EP1218004B1 5-methyl indirubin for use in the treatment of human solid tumors |
| 04/08/2009 | EP1096953B1 Use of inactivated immunosuppressive and/or angiogenic immunogenic proteins, preparation method and pharmaceutical or vaccine uses |
| 04/08/2009 | EP0961612B1 Protein stabilized pharmacologically active agents and their use |
| 04/08/2009 | EP0877758B1 PURIFIED SR-p70 PROTEIN |